N-(Hydroxymethyl) melamines

General Pharmacology

Volumn 28, Issue 2, 1997, Pages 177-182

  Coley, Helen M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

analogs; platinum; resistance; trimelamol

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CB 7518; CB 7541; CB 7547; CB 7639; CB 7646; CB 7669; CB 7682; CB 7683; CB 7706; N (HYDROXYMETHYL)MELAMINE DERIVATIVE; PLATINUM DERIVATIVE; TRIMELAMOL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GRAFT; CLINICAL TRIAL; CYTOTOXICITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ALTRETAMINE; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; TRIAZINES;

EID: 0031033725     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00172-3     Document Type: Review

References (32)

1. Ames M. M. (1991) Hexamethylmelamine: pharmacology and mechanism of action. Cancer Treat. Rev. 18, 3-14.
2. Buckley S. M., Stock C. C., Crossley M. L. and Rhoads C. P. (1950) Inhibition of the Crocker mouse sarcoma 180 by certain ethyleneimine derivatives and related compounds. Cancer Res. 10, 207-208.
3. Caspar E. S., Gralla R. J., Garrett R. L., Jones B. R., Woodcock T. M., Gordon C., Kelson D. P. and Young C. W. (1981) Phase 1 and pharmacological studies of pentamethylmelamine administered by a 24hr intravenous infusion. Cancer Res. 41, 1402-1406.
4. Coley H. M., Jarman M. and Judson I. R. (1993) Rationale for the development of stable water soluble analogues of the s-triazine trimelamol. AACR Meeting Proc., Abstract 2223, p. 373.
5. Coley H. M., Jarman M., Brooks N., Thornton T. J. and Judson I. R. (1994) Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines. Eur. J. Cancer 30A, 1827-1836.
6. Coley H. M., Brooks N., Philips D. H., Hewer A., Jenkins T. C., Jarman M. and Judson I. R. (1995) The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies. Biochem. Pharmac. 49, 1203-1212.
7. Coley H. M., Jarman M., Jones M., Sargent J. M., Kubota T., Lee N. C. J, Goddard P. M., Elgie A. W., Williamson C., Taylor C. G. and Judson I. R. (1996) The activity of N-hydroxymethyl)melamines in fresh human ovarian tumour cells and xenografts (in press).
8. Coley H. M., Jarman M., Brooks N., Goddard P. M., Jones M., Lee N., Kubota T., Halbert G., Owens M. and Harrap K. R. (1996) Preclinical development of the antitumour agent CB7646, bis N-(hydroxymethyl)trimethylinelamine, a stable analogue of trimelamol (in press).
9. Connors T. A., Cumber A. J., Ross W. C. J., Clarke S. A. and Mitchley B. C. V. (1977) Regression of human lung tumour xenografts induced by water-soluble analogues of hexamethylmelamine. Cancel-Treat. Rep. 61, 927-928.
10. Cumber A. J. and Ross W. C. J. (1977) Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chem. Biol. Interact. 17, 349-357.
11. D'Incalci M., Bolis G., Mangioni C., Morasca L. and Garattini S. (1978) Variable oral absorption of hexamethylmelamine in man. Cancer Treat. Rep. 62, 2117-2119.
12. D'Incalci M., Begglion G., Sessa C. and Mangioni C. (1981) Influence of ascites on the pharamcokinetics of hexamethylmelamine and N-demethylated metabolites on ovarian cancer patients. Eur. J. Cancer 17, 1331-1335.
13. Dubois J., Atassi G., Hanocq M. and Abikhali F. (1986) Pharmacokinetics and metabolism of hexamethylmelamine in mice after i.p. administration. Cancer Chemother. Pharmac. 18, 226-230.
14. Foster B. J., Harding B. J., Leyland-Jones B. and Hoth D. (1986) Hexamethylmelamine: a critical review of an active drug. Cancer Treat. Rev. 13, 197-217.
15. Gibson M., Denham A. J., Taylor P. T. and Payne N. I. (1990) Development of a patenteral formulation of trimelamol, a synthetic s-triazine carbinolamine-containing cytotoxic agent. J. Parent. Sci. Technol. 44, 306-313.
16. Hendry J. A., Homer R. F., Rose F. L. and Walpole A. L. (1951) Cytotoxic agents: III, derivatives of ethyleneimine. Br. J. Pharmac. 6, 357-410.
17. Jackson C., Crabb T. A., Gibson M., Russell G., Saunders R. and Thurston D. E. (1991) Studies on the stability of trimelamol, a carbinolamine-containing antitumour drug. J. Pharm. Sci. 80, 245-251.
18. Jarman M., Coley H. M., Judson I. R., Thornton T. J., Wilman D. E. V., Abel G. and Rutty C. J. (1993) Synthesis and cytotoxicity of potential tumour-inhibitory analogues of trimelamol (2,4,6,-tris[(hydroxymethyl)-methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl. J. Med. Chem. 36, 4195-4200.
19. 6-trimethylmelamine (trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. Br. J. Cancer 53, 601-606.
20. 6-trimediylmelamine. Cancer Res. 49, 5475-5479.
21. Judson I. R., Calvert A. H., Gore M. E., Balmonno K., Gumbrell L. A., Perren T. and Wiltshaw E. (1991) Phase II trial of trimelamol in refractory ovarian cancer. Br. J. Cancer 63, 311-313.
22. Kreilgard B. O., Higuchi T. and Repta A. J. (1975) Complexation in formulation of parenteral solutions: solubilisation of the cytotoxic agent hexamethylmelamine by complexation with gentissic acid species. J. Pharm. Sci. 64, 1850-1855.
23. Legha S. S., Slavik M. and Carter S. K. (1976) Hexamethylmelamine: an evaluation of its role in the therapy of cancer. Cancer 38, 27-35.
24. Pennock J., Godfrey R., Saunders R. W., Hartley J. A. and Thurston D. E. (1994) Relationship between cross-linking activity and cytotoxicity for a series of novel trimelamol analogues. In 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy (Abstract 055), p. 82. Amsterdam.
25. Ross W. E., McMillan D. R. and Ross C. F. (1981) Comparison of DNA damage by methylmelamines and formaldehyde. J. Natl. Cancer Inst. 67, 217-221.
26. Ross D. R., Langdon S. P., Gescher A. and Stevens M. F. G. (1984) Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism. Biochem. Pharamc. 33, 1131-1136.
27. Rutty C. J. and Connors T. A. (1977) In vitro studies with hexamethylmelamine. Biochem. Pharmac. 26, 2385-2391.
28. Rutty C. J. and Abel G. (1980) In vitro cytotoxicity of the methylmelamines. Chem. Biol. Interact. 29, 235-246.
29. Rutty C. J., Newell D. R., Muindi J. R. F. and Harrap K. R. (1982) The comparative pharmacokinetics of pentamethylmelamine in man, rat and mouse. Cancer Chemother. Pharmac. 8, 105-111.
30. 6-trimethylmelamine (Trimelamol), a water soluble cytotoxic s-triazine which does not require metabolic activation. Cancer Chemother. Pharmac. 17, 251-258.
31. Sessa C., Bolis G., Colombo N., D'Incalci M., Mermillod B., Valente and Mangioni C. (1985) Hexamethylmelamine, adriamycin and cyclophosphamide (HAC) versus cisdichlorodiamineplatinum, adriamycin and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial. Cancer Chemother. Pharmac. 14, 222-228.
32. Wilson W. L. and Del la Garza J. G. (1965) Phase I study of hexamethylmelamine (NSC-13875). Cancer Chemother. Rep. 48, 49-52.